AVITA Medical grants stock awards to director
AVITA Medical, Inc. granted equity awards to director Woody Joseph Fralin.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
AVITA Medical, Inc. granted equity awards to director Woody Joseph Fralin. On January 5, 2026, he received 40,547 restricted stock units (RSUs) and 29,446 stock options with a $3.47 exercise price, subject to stockholder approval obtained on June 3, 2026. On January 20, 2026, he received an additional 22,214 RSUs and 16,133 stock options with a $3.77 exercise price. The RSUs vest over time, and the options vest in three equal annual installments, providing long-term, stock-based compensation. Following these awards, his direct common stock holdings increased to 82,761 shares.
Insider Trade Summary
Grant/Award: 108,340 shares
Grant/Award
4 txns
Insider
Woody Joseph Fralin
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (Right to Buy) | 16,133 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 22,214 | $0.00 | $0.00 |
| Grant/Award | Stock Options (Right to Buy) | 29,446 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 40,547 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options (Right to Buy) — 45,579 contracts (Direct);
Common Stock — 82,761 shares (Direct)
Footnotes (6)
- F1. Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments on the date 12 months following the grant date of January 5, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
- F2. Includes unvested RSUs
- F3. Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
- F4. On January 5, 2026, the Board of Directors approved a grant of 29,446 options to acquire 29,446 shares of Common Stock of the Company to Mr. Woody as a new non-executive director, with an effective grant date of January 5, 2026 and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on January 5, 2026 of $3.47. The grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
- F5. These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date.
- F6. On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
Key Figures
RSUs granted Jan 5, 2026: 40,547 RSUs
RSUs granted Jan 20, 2026: 22,214 RSUs
Options Jan 5, 2026: 29,446 options at $3.47
+4 more
7 metrics
RSUs granted Jan 5, 2026
40,547 RSUs
Restricted stock units granted to director on January 5, 2026
RSUs granted Jan 20, 2026
22,214 RSUs
Restricted stock units granted to director on January 20, 2026
Options Jan 5, 2026
29,446 options at $3.47
Stock options granted to new non-executive director on January 5, 2026
Options Jan 20, 2026
16,133 options at $3.77
Stock options granted to each non-executive director on January 20, 2026
Shares after Jan 20 grants
82,761 shares
Total direct common stock holdings following January 20, 2026 grant
Option expiry Jan 5 grant
Expires January 5, 2036
Expiration date of 29,446 stock options granted January 5, 2026
Option expiry Jan 20 grant
Expires January 20, 2036
Expiration date of 16,133 stock options granted January 20, 2026
Key Terms
restricted stock units, RSUs, Stock Options (Right to Buy), exercise price, +2 more
6 terms
restricted stock units financial
"Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"These RSUs vest in three equal annual installments on the date 12 months following the grant date of January 5, 2026."
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy) with an exercise price equal to the closing price on Nasdaq on January 5, 2026 of $3.47."
exercise price financial
"an exercise price equal to the closing price of a share of Common Stock on Nasdaq on January 5, 2026 of $3.47."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
non-executive director financial
"29,446 options to acquire 29,446 shares of Common Stock of the Company to Mr. Woody as a new non-executive director"
A non-executive director is a member of a company’s board who does not work for the company day-to-day but provides independent oversight, strategic guidance and checks on management. For investors, they matter because they act like an impartial referee or outside advisor, helping ensure decisions protect shareholder interests, reduce risks of poor governance, and add credibility to financial reporting and long-term strategy.
time-based vesting criteria financial
"that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did AVITA Medical (RCEL) report for director Woody Joseph Fralin?
AVITA Medical reported equity awards to director Woody Joseph Fralin, including restricted stock units and stock options. These were compensation-related grants, not open-market purchases or sales, and increase his equity stake through time-based vesting rather than immediate cash transactions.
How many AVITA Medical (RCEL) RSUs were granted to Woody Joseph Fralin?
Fralin received 40,547 restricted stock units on January 5, 2026, and 22,214 RSUs on January 20, 2026. Each RSU represents a contingent right to one share of AVITA Medical common stock, subject to time-based vesting conditions approved by stockholders on June 3, 2026.
What stock options did AVITA Medical (RCEL) grant to Woody Joseph Fralin and at what prices?
He was granted 29,446 stock options on January 5, 2026 at a $3.47 exercise price and 16,133 options on January 20, 2026 at a $3.77 exercise price. These options allow future share purchases at those prices if vesting and exercise conditions are met.
How do the AVITA Medical (RCEL) RSU awards to Woody Joseph Fralin vest?
The RSUs granted on January 5, 2026 vest in three equal annual installments starting 12 months after the grant date. The RSUs granted on January 20, 2026 vest in full 12 months after that grant date, aligning compensation with ongoing board service over time.
When do Woody Joseph Fralin’s AVITA Medical (RCEL) stock options expire?
The options granted on January 5, 2026 expire on January 5, 2036, while those granted on January 20, 2026 expire on January 20, 2036. Both grants vest in three equal annual installments, providing a long exercise window following full vesting of the awards.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates